Effects of Coenzyme Q10 on Heart Health in People at Risk for Metabolic Syndrome

Effects of Coenzyme Q10 Supplement on Cardiovascular Risk Factors in Subjects at High Risk of Metabolic Syndrome

This study is testing if taking coenzyme Q10 can help improve heart health and lower risks for people at high risk for metabolic syndrome.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 150 (estimated)
• Ages: 30 Years to 90 Years
• Sex: All
• Sponsor: Sun Yat-sen University (Academic / other)
• Locations: 1 site (Shenzhen)
• Trial ID: NCT06506630 on ClinicalTrials.gov

What this trial studies

This study evaluates how coenzyme Q10 supplementation can improve cardiovascular risk factors in individuals at high risk for metabolic syndrome. Participants will be assessed for changes in blood lipid levels, insulin resistance, blood pressure, platelet function, endothelial function, cardiorespiratory fitness, and muscle function. The study involves a comparison between those receiving coenzyme Q10 and a placebo group. The goal is to determine if this supplement can effectively reduce cardiovascular risks in this population.

Who should consider this trial

Good fit: Ideal candidates are adults aged 30-90 with metabolic syndrome or at least two risk factors for metabolic syndrome.

Not a fit: Patients without metabolic syndrome or those who do not meet the risk factor criteria may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved cardiovascular health and reduced risk of metabolic syndrome in high-risk individuals.

How similar studies have performed: Other studies have shown promising results with coenzyme Q10 supplementation in improving cardiovascular health, suggesting potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* Metabolic syndrome or high-risk groups with metabolic syndrome are defined as subjects with metabolic syndrome according to the International Diabetes Federation (IDF) Chinese Adult Criteria, and high-risk groups are defined as those who meet at least two MetS risk factors. The specific criteria are as follows:

  1. Aged 30-90 years old;
  2. Two or more of following are acceptable:

  <!-- -->

  1. Abdominal obesity (central obesity): waist circumference \>=90 cm for men and \>=80cm for women;
  2. Hyperglycemia: fasting blood glucose ≥ 5.6mmol/L or taking hypoglycemic drugs;
  3. Hypertension: systolic blood pressure \>=130mmHg and (or) diastolic blood pressure \>=85mmHg or taking blood pressure medications;
  4. Fasting TG\>=1.70mmol/L or taking antihyperlipidemic drug;
  5. Fasting HDL-C\<1.04 mmol/L for men, \<1.29 mmol/L for women or taking antihyperlipidemic drug; 3) Sign informed consent and insist on participating in the research.

Exclusion Criteria:

* 1\) Take drugs/dietary supplements, such as aspirin, fish oil and etc., that affect platelet function in recently six months; 2) blood system disease or infection; 3) Blood pressure \>=160/100mmHg; 4) Low platelet count (whole blood platelet\<100 x 10\^9/mL); 5) Abnormal hemoglobin (male \<120g/L, female \<110g/L); 6) Low hematocrit (male \<40%, female \<37%); 7) Prothrombin time (PT) is outside the normal reference range; 8) Pregnant women or nursing mothers; 9) Abnormal menstrual cycle, taking birth control pills or hormone replacement therapy; 10) Gastric ulcer, liver or kidney dysfunction.

Where this trial is running

Shenzhen

• School of Public Health (Shenzhen), Sun Yat-sen University — Shenzhen, China (Recruiting)

Study contacts

• Study coordinator: yan yang

Conditions Metabolic Syndrome; Cardiovascular Diseases